Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.28 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: mm-111, kbp5209, lapatinib ditosylate +45 | 1.00 |
| trials ClinicalTrials.gov | 9 Parkinson's trials, 1 stopped | 0.91 |
| literature PubMed | 13 Parkinson's papers of 11,523 | 0.65 |
| pathways Reactome | 33 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 1376
Sealed predictions
- ERBB2 in dopamine neurons, braak-0.61 (p 0.083) → -0.46 (p 0.212)receipt 1383
Swarm cases
receipt 1383: ERBB2 in dopamine neurons, braak
- power
- full sample -0.44 (p 0.067, n 18), 95% CI -0.75 to +0.03. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.43 (p 0.077, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.63 (p 0.0053, n 18). not the mix.
- skeptic
- leave-one-out range -0.56 to -0.37, sign flips 0; without severely affected donors -0.44 (p 0.067, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ERBB2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts